Sign in or create an account to add this stock to your watchlist.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SHP
CUSIPN/A
Phone+353-1-6096000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins16.73%
Return on Equity8.11%
Return on Assets4.11%
Miscellaneous
EmployeesN/A
Outstanding Shares908,640,000
Shire (LON:SHP) Frequently Asked Questions
What is Shire's stock symbol?
Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."
How often does Shire pay dividends? What is the dividend yield for Shire?
Shire announced a dividend on Wednesday, February 14th. Investors of record on Thursday, March 8th will be given a dividend of GBX 21.46 per share on Tuesday, April 24th. This represents a yield of 0.67%. The ex-dividend date is Thursday, March 8th. This is a positive change from Shire's previous dividend of $3.85. The official announcement can be seen at this link. View Shire's Dividend History.
What price target have analysts set for SHP?
20 brokers have issued twelve-month price targets for Shire's stock. Their forecasts range from GBX 3,559 to GBX 8,000. On average, they anticipate Shire's stock price to reach GBX 4,600.75 in the next twelve months. View Analyst Ratings for Shire.
Who are some of Shire's key competitors?
Some companies that are related to Shire include CSL (CSL), UCB (UCBJY), Genmab (GMXAY), Ablynx (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF) and Mesoblast (MSB).
Who are Shire's key executives?
Shire's management team includes the folowing people:
- Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
- Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
- Gisele Dion, Chief Accounting Officer
- Mr. Matthew Walker, Head of Technical Operations (Age 54)
- Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55)
Has Shire been receiving favorable news coverage?
Media stories about SHP stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a news sentiment score of 0.01 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Shire?
Shares of SHP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Shire's stock price today?
One share of SHP stock can currently be purchased for approximately GBX 4,199.
How big of a company is Shire?
Shire has a market capitalization of £29.14 billion.
How can I contact Shire?
Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.
MarketBeat Community Rating for Shire (SHP)
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shire (LON:SHP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is GBX 4,600.75The high price target for SHP is GBX 8,000 and the low price target for SHP is GBX 3,559. There are currently 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.85 | 2.85 | 2.88 | 2.89 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 4,600.75 | GBX 4,573.30 | GBX 5,243.75 | GBX 5,344.12 |
Shire (LON:SHP) Consensus Price Target History
Shire (LON:SHP) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 5/11/2018 | Kepler Capital Markets | Upgrade | Buy | GBX 4,550 |  |
| 5/9/2018 | Deutsche Bank | Reiterated Rating | Buy | | |
| 5/8/2018 | Liberum Capital | Reiterated Rating | Hold | | |
| 5/8/2018 | Berenberg Bank | Reiterated Rating | Buy | | |
| 5/8/2018 | Shore Capital | Lower Price Target | Buy | GBX 4,025 ➝ GBX 3,856 | |
| 5/4/2018 | Credit Suisse Group | Reiterated Rating | Outperform | | |
| 4/25/2018 | Royal Bank of Canada | Reiterated Rating | Outperform | | |
| 4/20/2018 | Cfra | Set Price Target | Buy | GBX 4,500 | |
| 4/9/2018 | BNP Paribas | Reiterated Rating | Outperform | GBX 4,700 | |
| 4/4/2018 | Societe Generale | Set Price Target | Buy | GBX 7,500 | |
| 4/3/2018 | Sanford C. Bernstein | Set Price Target | Buy | GBX 4,400 | |
| 3/29/2018 | HSBC | Reiterated Rating | Hold | | |
| 3/28/2018 | Main First Bank | Initiated Coverage | Outperform | GBX 3,600 | |
| 3/28/2018 | Jefferies Group | Reiterated Rating | Buy | GBX 4,100 | |
| 3/27/2018 | Morgan Stanley | Reiterated Rating | Overweight | GBX 4,700 | |
| 3/26/2018 | Goldman Sachs | Reiterated Rating | Conviction-Buy | GBX 4,600 | |
| 2/21/2018 | Citigroup | Reiterated Rating | Buy | GBX 5,500 | |
| 2/20/2018 | JPMorgan Chase | Downgrade | Neutral | GBX 5,000 ➝ GBX 3,600 | |
| 2/15/2018 | Barclays | Reiterated Rating | Equal weight | GBX 3,650 | |
| 1/29/2018 | Investec | Reiterated Rating | Buy | GBX 8,000 | |
| 8/4/2017 | Beaufort Securities | Reiterated Rating | Long Term Buy | GBX 6,200 ➝ GBX 4,900 | |
| 2/16/2017 | UBS | Reiterated Rating | Neutral | GBX 5,000 | |
| 1/9/2017 | Bryan, Garnier & Co | Reiterated Rating | Buy | GBX 6,800 | |
| 11/7/2016 | AlphaValue | Reiterated Rating | Buy | GBX 6,714 | |
| 11/3/2016 | Bank of America | Reiterated Rating | Buy | GBX 6,970 | |
(Data available from 5/20/2016 forward)
Shire (LON:SHP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/14/2018 | | GBX 21.46 | 0.67% | 3/8/2018 | 3/8/2018 | 4/24/2018 |
| 8/3/2017 | | GBX 3.85 | 0.1% | 9/7/2017 | 9/7/2017 | 10/20/2017 |
| 2/16/2017 | | GBX 20.64 | 0.43% | 3/9/2017 | 3/9/2017 | 4/25/2017 |
| 8/2/2016 | | GBX 3.51 | 0.07% | 9/8/2016 | 9/8/2016 | 10/7/2016 |
| 2/11/2016 | | GBX 15.32 | 0.44% | 3/10/2016 | 3/10/2016 | 4/12/2016 |
| 7/23/2015 | | GBX 2.69 | 0.05% | 9/3/2015 | 9/3/2015 | 10/2/2015 |
| 7/18/2014 | | GBX 2.24 | 0.04% | 9/3/2014 | 9/3/2014 | 10/3/2014 |
| 2/13/2014 | | GBX 10.21 | 0.31% | 3/5/2014 | 3/5/2014 | 4/8/2014 |
(Data available from 1/1/2013 forward)
Shire (LON SHP) Insider Trading and Institutional Ownership History
Shire (LON SHP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/14/2018 | Mark Clayton Jarvis | Director | Sell | 365,000 | GBX 0.06 | £219 | | |
| 12/19/2017 | Dominic Blakemore | Insider | Buy | 165 | GBX 3,790 | £6,253.50 | | |
| 9/29/2017 | Anne Minto | Insider | Buy | 190 | GBX 3,785 | £7,191.50 | | |
| 8/22/2017 | Flemming Ornskov | Insider | Buy | 8,400 | GBX 3,665 | £307,860 | | |
| 6/30/2017 | Dominic Blakemore | Insider | Buy | 152 | GBX 4,255 | £6,467.60 | | |
| 3/31/2017 | William Burns | Insider | Buy | 136 | GBX 4,742 | £6,449.12 | | |
| 12/16/2016 | Olivier Bohuon | Insider | Buy | 141 | GBX 4,528 | £6,384.48 | | |
| 9/30/2016 | Dominic Blakemore | Insider | Buy | 133 | GBX 5,010 | £6,663.30 | | |
| 6/30/2016 | Bohuon,Olivier | Insider | Buy | 134 | GBX 4,463 | £5,980.42 | | |
| 3/31/2016 | Bohuon,Olivier | Insider | Buy | 133 | GBX 3,908 | £5,197.64 | | |
| 2/15/2016 | Bohuon,Olivier | Insider | Buy | 1,000 | GBX 3,552 | £35,520 | | |
| 2/12/2016 | Burns,William | Insider | Buy | 1,250 | GBX 3,563 | £44,537.50 | | |
| 12/18/2015 | Burns,William | Insider | Buy | 156 | GBX 4,457 | £6,952.92 | | |
| 9/30/2015 | Blakemore ,Dominic | Insider | Buy | 129 | GBX 4,498 | £5,802.42 | | |
| 6/30/2015 | Kappler,David J | Insider | Buy | 126 | GBX 51.05 | GBX 6,432.30 | | |
| 3/31/2015 | Susan Kilsby | Insider | Buy | 375 | GBX 5,327 | £19,976.25 | | |
| 12/19/2014 | Steven Gillis | Insider | Buy | 228 | GBX 4,654 | £10,611.12 | | |
| 10/30/2014 | Steven Gillis | Insider | Buy | 381 | GBX 4,098 | £15,613.38 | | |
(Data available from 1/1/2013 forward)
Shire (LON SHP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Biogen, Shire called out by FDA for 'gaming' generic access rule
www.bizjournals.com - May 17 at 6:10 PM |
 | Takeda CEO Sees Path to Survival in Shire Megadeal
www.bloomberg.com - May 16 at 5:31 PM |
 | Global Eating Disorders Market 2018-2028: Shire Leads Industry Sponsors with the Highest Number of Clinical Trials
www.prnewswire.com - May 14 at 5:14 PM |
 | Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?
finance.yahoo.com - May 14 at 5:14 PM |
 | Shire (SHP) Lifted to "Buy" at Kepler Capital Markets
www.americanbankingnews.com - May 11 at 9:53 AM |
| Shire (SHP) Lowered to "Under Review" at Kepler Capital Markets
www.americanbankingnews.com - May 10 at 2:19 PM |
| Whisky and Apologies Aided Takeda's $62 Billion Gamble on Shire
finance.yahoo.com - May 10 at 8:32 AM |
| Takeda's Credit Rating Cut by Moody's on $62 Billion Shire Deal
www.bloomberg.com - May 9 at 5:26 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Shire plc And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - May 9 at 5:26 PM |
| Shire (SHP) Rating Reiterated by Deutsche Bank
www.americanbankingnews.com - May 9 at 8:52 AM |
 | Takeda to takeover bigger rival Shire in $62bln deal
www.usatoday.com - May 8 at 5:30 PM |
| Takeda Agrees to Buy Shire in Cash, Share Deal
www.bloomberg.com - May 8 at 5:30 PM |
| Oil pares losses after U.S. exits Iran deal, dollar off 2018 highs
finance.yahoo.com - May 8 at 5:30 PM |
| Takeda aims to boost rare disease profile with Shire deal, says R&D chief
finance.yahoo.com - May 8 at 5:30 PM |
| FTSE edges lower, but ends near 14-week high as oil’s drop offsets Shire stock rally
finance.yahoo.com - May 8 at 5:30 PM |
| Shire (SHP) Receives "Hold" Rating from Liberum Capital
www.americanbankingnews.com - May 8 at 11:48 AM |
| Berenberg Bank Reiterates "Buy" Rating for Shire (SHP)
www.americanbankingnews.com - May 8 at 7:04 AM |
| Shore Capital Trims Shire (SHP) Target Price to GBX 3,856
www.americanbankingnews.com - May 8 at 7:04 AM |
 | Takeda closing in on Shire
seekingalpha.com - May 7 at 5:30 PM |
| Shire (SHP) Receives Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - May 5 at 1:07 AM |
| Shire plc : Director/PDMR Shareholding
finance.yahoo.com - May 1 at 5:11 PM |
| Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
finance.yahoo.com - April 27 at 5:09 PM |
| Shire (SHP) Receives "Buy" Rating from Kepler Capital Markets
www.americanbankingnews.com - April 27 at 9:17 AM |
 | BRIEF-Shire declines to comment on Takeda, any further disposals
www.reuters.com - April 26 at 5:11 PM |
| Shire Plc (SHPG) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 5:11 PM |
| Is Shire plc’s (LON:SHP) Balance Sheet A Threat To Its Future?
finance.yahoo.com - April 26 at 5:11 PM |
| Shire's (SHP) Buy Rating Reiterated at Deutsche Bank
www.americanbankingnews.com - April 26 at 10:08 AM |
| Shire (SHP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 26 at 9:38 AM |
| Shire's (SHP) "Hold" Rating Reaffirmed at Liberum Capital
www.americanbankingnews.com - April 25 at 11:30 AM |
| Shire's (SHP) "Outperform" Rating Reaffirmed at Royal Bank of Canada
www.americanbankingnews.com - April 25 at 10:42 AM |
| Shire (SHP) Price Target Raised to GBX 4,025
www.americanbankingnews.com - April 25 at 9:22 AM |
| [$$] Takeda Nears Shire Deal as Japan Inc. Chases Growth Overseas
finance.yahoo.com - April 25 at 8:28 AM |
| Shire willing to back $64 bln Takeda bid, market signals doubts
finance.yahoo.com - April 25 at 8:28 AM |
 | Shire, Takeda reach breakthrough in merger talks, says Reuters
www.cnbc.com - April 24 at 5:29 PM |
| Amid a Boisterous Takeover, Shire Investor Meeting Keeps Calm
www.bloomberg.com - April 24 at 5:29 PM |
| Shire receives yet another bid from Takeda as takeover deadline looms
www.cnbc.com - April 24 at 5:29 PM |
| Exclusive: Shire, Takeda reach breakthrough in deal talks - sources
finance.yahoo.com - April 24 at 5:29 PM |
| Shire Pops On Report A Takeover Deal With Takeda Is Imminent
finance.yahoo.com - April 24 at 5:29 PM |
 | Takenda Near Preliminary Agreement to Acquire Shire (SHPG) - Bloomberg
www.streetinsider.com - April 24 at 8:26 AM |
 | Shire weighs fresh approach from Japan's Takeda
www.ft.com - April 24 at 8:26 AM |
| Form 8-K Shire plc For: Apr 23
www.streetinsider.com - April 23 at 5:07 PM |
| Shire plc : Holding(s) in Company
finance.yahoo.com - April 23 at 5:07 PM |
| Takeda Can't Kick Its Shire Habit
finance.yahoo.com - April 23 at 5:07 PM |
| Shire (SHPG) PT Raised to $186 at RBC Capital; Potential Deal to Overshadow Results
www.streetinsider.com - April 23 at 8:21 AM |
| Shire (SHP) Rating Reiterated by Liberum Capital
www.americanbankingnews.com - April 20 at 6:56 PM |
| Shire (SHP) Rating Reiterated by Shore Capital
www.americanbankingnews.com - April 20 at 6:54 PM |
| Shire's (SHP) "Buy" Rating Reaffirmed at Deutsche Bank
www.americanbankingnews.com - April 20 at 5:18 PM |
| Shire (SHP) Earns "Overweight" Rating from JPMorgan Chase
www.americanbankingnews.com - April 20 at 5:18 PM |
 | Shire Pandemonium, Aluminum Glut, ZTE Fallout: CEO Daily for April 20, 2018
fortune.com - April 20 at 5:15 PM |
| Takeda increases bid for Shire
www.cnbc.com - April 20 at 5:15 PM |
Shire (LON:SHP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Shire (LON SHP) Stock Chart for Sunday, May, 20, 2018
Loading chart…
